Mereo BioPharma Group (NASDAQ:MREO) reported quarterly losses of $(0.02) per share which missed the analyst consensus estimate of $(0.01) by 100 percent. This is unchanged from the same period last year. The company reported $500.000 thousand in sales this quarter.